By Hendra Lukman 
Stanford Medicine researchers have achieved a groundbreaking success in preclinical studies, demonstrating that the simultaneous transplantation of immunologically mismatched blood-forming stem cells and pancreatic islet cells can either completely prevent or fully reverse Type 1 diabetes in mice. This innovative strategy hinges on the creation of a "hybrid immune system" within the recipient, effectively retraining the body’s defenses to tolerate both the donor cells and its own insulin-producing tissues. The findings, published in the Journal of Clinical Investigation, offer a beacon of hope for millions worldwide affected by this chronic autoimmune disease.
The Autoimmune Challenge of Type 1 Diabetes
Type 1 diabetes is characterized by a devastating autoimmune attack where the body’s own immune system mistakenly identifies and destroys the insulin-producing beta cells located within the islets of Langerhans in the pancreas. Insulin is a critical hormone responsible for regulating blood sugar levels by allowing glucose to enter cells for energy. Without sufficient insulin, glucose accumulates in the bloodstream, leading to hyperglycemia and a cascade of serious long-term complications affecting the eyes, kidneys, nerves, and cardiovascular system. Currently, the only available treatments involve lifelong management with insulin therapy and constant blood glucose monitoring, which can be burdensome and do not fully prevent disease progression.
A Novel Two-Pronged Therapeutic Strategy
The cornerstone of this new approach lies in the dual transplantation. The research team, led by Seung K. Kim, MD, PhD, a professor at Stanford Medicine, administered both hematopoietic stem cells (which give rise to all blood and immune cells) and pancreatic islet cells from donors who were not genetically matched to the recipient mice. Crucially, this combined transplant was performed without inducing graft-versus-host disease (GVHD), a potentially life-threatening complication in which the transplanted immune cells attack the recipient’s healthy tissues.
In this study, none of the recipient mice developed GVHD. Instead, the transplanted blood stem cells appear to have successfully "educated" the recipient’s immune system. This re-education process resulted in the immune system no longer recognizing the transplanted islet cells as foreign invaders. Furthermore, and perhaps more significantly, it also halted the recipient’s original immune system from continuing its assault on any remaining or newly transplanted islet cells.
The implications of this immune system recalibration are profound. Following the transplants, the mice no longer required immune-suppressive drugs, a common necessity in organ transplantation to prevent rejection, nor did they need insulin injections throughout the six-month study period. This indicates a restoration of normal glucose homeostasis achieved through the body’s own restored cellular function.
Building on Previous Successes: The Evolution of the Protocol
This latest breakthrough builds upon earlier work conducted by Dr. Kim and his colleagues in 2022. In their previous study, researchers induced diabetes in mice by administering toxins to destroy their islet cells. They then employed a pre-transplant conditioning regimen that included immune-targeting antibodies and low-dose radiation, followed by a transplant of blood stem cells and islet cells from an unrelated donor. This earlier protocol successfully restored blood sugar control in the induced diabetes model.
However, the 2022 study focused on overcoming the immune system’s rejection of donor cells. The current research tackles a more formidable challenge: preventing or curing diabetes driven by an autoimmune attack, where the immune system is inherently predisposed to target islet cells. In the context of human Type 1 diabetes, the immune system spontaneously initiates this destructive process. The current study’s model therefore presented a dual threat to the transplanted islets: they were perceived as foreign by the recipient’s immune system, and this same immune system was already primed to destroy islet cells from any source.
"Just like in human Type 1 diabetes, the diabetes that occurs in these mice results from an immune system that spontaneously attacks the insulin-producing beta cells in pancreatic islets," explained Dr. Kim. "We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals."
A Key Tweak for Robust Protection
Addressing the complexities of an autoimmune predisposition, the research team introduced a crucial modification to their pre-transplant conditioning. By incorporating a medication commonly used to treat autoimmune diseases into the established protocol, they achieved complete protection against the development of Type 1 diabetes in 19 out of 19 mice that received the combined transplant. This adjusted regimen, involving a carefully orchestrated combination of immune-modulating antibodies, low-dose radiation, and the autoimmune medication, facilitated the development of the desired hybrid immune system.
In a separate cohort of mice that already had established Type 1 diabetes, this refined combined transplantation strategy proved curative in all nine subjects treated. These animals, which had long-standing diabetes, were able to achieve normal blood sugar levels without further intervention after receiving the transplant.
The significance of this adjustment lies in its potential for clinical translation. The components of the pre-transplant regimen—antibodies, drugs, and low-dose radiation—are already integral to standard clinical practices for blood stem cell transplantation, particularly in cancer therapy. This familiarity with the underlying methodologies enhances the feasibility of moving this strategy towards human trials.
Laying the Groundwork: From Kidney Tolerance to Hybrid Immunity
The scientific underpinnings of this research are deeply rooted in decades of work exploring immune tolerance. Notably, this study draws upon pioneering research led by the late Samuel Strober, MD, PhD, a distinguished professor of immunology and rheumatology at Stanford, and his collaborators, including study co-author Judith Shizuru, MD, PhD, a professor of medicine. Their previous investigations demonstrated that bone marrow transplants from partially immunologically matched human donors could establish a hybrid immune system in recipients. This hybrid immunity, in turn, enabled the long-term acceptance of kidney transplants from the same donor without the need for chronic immunosuppressive drugs. In some instances, patients maintained stable kidney function for decades, a testament to the power of immune re-education.
While blood stem cell transplants are a well-established treatment for hematological malignancies like leukemia and lymphoma, these procedures typically involve aggressive chemotherapy and radiation regimens to eradicate the patient’s existing blood and immune system. These high-intensity conditioning protocols are associated with significant side effects. In contrast, Dr. Shizuru and her team have been instrumental in developing less intensive, safer conditioning approaches for non-cancerous conditions. Their methods aim to modulate bone marrow activity just enough to allow donor blood stem cells to engraft and flourish, thereby minimizing toxicity for patients with conditions like Type 1 diabetes.
"Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases," stated Dr. Shizuru. "The challenge has been to devise a more benign pre-treatment process, diminishing risk to the point that patients suffering from an autoimmune deficiency that may not be immediately life-threatening would feel comfortable undergoing the treatment."
The current study appears to have met this challenge by demonstrating that the donated blood stem cells can effectively "re-educate" the recipient’s immune system. This re-education not only ensures the acceptance of transplanted islets but also prevents the immune system from attacking the body’s own healthy tissues, including its own islets. Crucially, the donor immune cells also learn to coexist peacefully with the recipient’s tissues, thereby avoiding GVHD.
Navigating Future Hurdles and Expanding Horizons
Despite the highly encouraging results in mouse models, significant obstacles remain before this transformative therapy can be widely applied to treat Type 1 diabetes in humans. A primary limitation is the current scarcity of pancreatic islets for transplantation. Islets are exclusively sourced from deceased donors, and the blood stem cells must originate from the same individual as the islets to achieve the desired immunological compatibility. Furthermore, the number of islet cells typically recovered from a single donor may not always be sufficient to fully reverse established Type 1 diabetes, particularly in individuals with a long history of the disease.
The Stanford team is actively pursuing innovative solutions to these challenges. Strategies under investigation include the laboratory-scale production of large quantities of islet cells from pluripotent human stem cells. Researchers are also exploring methods to enhance the survival and functional efficiency of transplanted donor islets post-transplantation.
Beyond Type 1 diabetes, Dr. Kim, Dr. Shizuru, and their collaborators believe that their refined, gentler pre-conditioning strategy holds immense promise for a broader spectrum of autoimmune diseases. Conditions such as rheumatoid arthritis and lupus, as well as non-cancerous blood disorders like sickle cell anemia, could potentially benefit from stem cell transplantation using this less toxic approach. Moreover, the strategy might pave the way for transplants of mismatched solid organs, reducing the reliance on finding perfectly matched donors.
"The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances," Dr. Kim concluded. The research team’s dedication to overcoming the complexities of immune tolerance and autoimmune disease promises to reshape the landscape of regenerative medicine and autoimmune therapies in the years to come.
The study received funding from the National Institutes of Health, Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center.